Magnitude of metabolic syndrome and its predictors among patients on second-generation antipsychotic drugs at six psychiatry clinics and mental hospitals, in Addis Ababa, Ethiopia, 2019; Multicenter cross-sectional study

Amogne, Getasew; Alemu, Tekie; Tadesse, Trhas; Mullu, Assefa

doi:10.1016/j.dsx.2021.102187

Cited by 2 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The report from Kenya was slightly higher at 28.6% [ 33 ]. Three studies conducted in the central, south, and western part of the Ethiopia among patients with psychiatric illness, diagnosed with schizophrenia, major depressive disorder, bipolar disorder and others, reported prevalence of MetS ranged from 18 to 25% [ 14 – 16 ]. Our finding is comparable to those reported by previous studies even though our study include only patients diagnosed with schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

“…In Ethiopia, the prevalence of MetS among the general population has been recently determined in a large sample size, but evidence about the prevalence of MetS among patients with schizophrenia in low income countries is scarce. Few studies were conducted in Ethiopia, particularly in capital city (Addis Ababa), southern and western part of Ethiopia, to assess the prevalence of MetS among patients with psychiatric illness [ 14 – 16 ]. The aim of this study was to investigate the prevalence of MetS among patients with schizophrenia in Ethiopia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia

et al. 2021

View full text Add to dashboard Cite

Background Globally, the prevalence of metabolic syndrome (MetS) is higher among patients with schizophrenia than the general population, and this leads to higher morbidity and mortality in this population. The aim of this study was to investigate the MetS prevalence among patients with schizophrenia in Ethiopia. Methods We conducted a cross-sectional analysis of baseline data of 200 patients with schizophrenia recruited from Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. Lipid profile and blood glucose levels were measured using Roche Cobas 6000 clinical chemistry analyzer. The prevalence of MetS was assessed based on National Cholesterol Education Program Adult Treatment Panel III criteria. Patients’ demographic information, clinical and laboratory data, lifestyle habits, particularly smoking and Khat chewing, were evaluated vis-à-vis MetS. Results The overall prevalence of MetS in patients with schizophrenia was 21.5% (17.1% male, 29.6% female) where Low HDL-cholesterol value was the most common metabolic disorders components in both males and females subgroups. In the multivariate analysis, the positive and negative symptoms score (PANSS, AOR = 1.03, 95% CI 1.001–1.054) was associated factors with MetS. Conclusion In Ethiopia, patients with schizophrenia were found to have higher prevalence of MetS than the general population. Physicians/health care providers should routinely screen patients with schizophrenia for MetS and initiate timely management of those who develop the syndrome to reduce the health cost from caring for NCDs, improve the patients’ quality of life, and prevent premature mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Altogether, SSD core symptoms can be differentiated between positive symptoms (e.g., hallucinatory experiences, delusional beliefs), negative symptoms (e.g., lack of motivation, affective flattening, alogia, and social withdrawal), and cognitive impairment (difficulties in attention, memory, and executive functioning) ( 2 ). SSD are frequently accompanied by comorbidities such as depression, anxiety ( 3 , 4 ), and metabolic syndrome due to side effects of antipsychotic medication ( 5 , 6 ). Approximately half of the affected individuals undergo extensive hospital-stays ( 7 ), with an average treatment duration between 21 and 32 days for in-patients with SSD in Germany ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

Mechanisms of action and processes of yoga-based group intervention for inpatients with schizophrenia spectrum disorders–A longitudinal qualitative study

Töbelmann

Hahne²,

Schulze³

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

BackgroundResearch exploring the effects of yoga therapy (YT) on individuals with schizophrenia spectrum disorders (SSD) is scarce. Therefore, the current study aimed to explore possible mechanisms of actions and processes, as well as adverse effects of a novel yoga-based group intervention (YoGI) for in-patients with SSD in a German university hospital setting.Material and methodsA longitudinal qualitative study was integrated into a rater-blinded randomized controlled trial, exploring the impact of a 4-week YoGI as add-on treatment. In-depth interviews were conducted with participants receiving YoGI (n = 19) in addition to treatment as usual (TAU) and a control group (n = 14) which only received TAU. Interviews were conducted at baseline (n = 33) and 4 weeks post-intervention (N = 28) to assess the participant’s experiences and how they changed over time. The interviews (N = 61) were audio-taped, translated, coded, and analyzed by means of inductive thematic analysis. Separate case summaries were prepared for each participant to analyze longitudinal changes within subjects. The research team members collaboratively discussed the final list of themes and subcodes. Rater-based questionnaires, such as the Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), and Personal and Social Performance Scale (PSP) were administered at baseline to assess clinical outcomes.ResultsAt baseline, participants reported a desire to improve their stress- and symptom management. A minority of participants expressed reservations toward yoga, and several psychosocial barriers were named, including worries about symptom exacerbation. At post-intervention, four mechanisms of change became evident from the interviews: (1) acquiring competence in relaxation, (2) increased interoceptive awareness, (3) feeling connected, and (4) a sense of spiritual wellbeing. A small number of participants reported difficulties with YoGI.ConclusionGenerally, YoGI positively influenced participants’ experiences of their inpatient stay, regarding distress, self- and body awareness, social connectedness, and spiritual wellbeing. However, participants also illuminated necessary adjustments to improve the intervention. YoGI will therefore be adapted and further developed in an iterative process based on a participant involvement approach. The efficacy regarding outcomes and processes needs to be investigated in a future larger-scaled randomized controlled trial.

show abstract

Magnitude of metabolic syndrome and its predictors among patients on second-generation antipsychotic drugs at six psychiatry clinics and mental hospitals, in Addis Ababa, Ethiopia, 2019; Multicenter cross-sectional study

Cited by 2 publications

References 9 publications

Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia

Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia

Mechanisms of action and processes of yoga-based group intervention for inpatients with schizophrenia spectrum disorders–A longitudinal qualitative study

Contact Info

Product

Resources

About